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To the Editor: 41 
 42 
Second primary cancers (SPCs) are becoming more common as the survival in cancer is 43 
improving, and they are of main concern in cancers of good survival because they may cause early 44 
mortality. Here we want to test the hypothesis that the type of SPC is critical for survival and we 45 
further posit that the survival time can be predicted from the fatality of these cancers as first 46 
primary cancers. We test the hypotheses on two leukemias with good survival, with the common 47 
chronic lymphocytic leukemia (CLL) and the rare hairy cell leukemia (HCL). In the comparison of 48 
survival rates we use relative survival to avoid biases in the definition of the cause of death.    49 
    50 
CLL is characterized by the gradually accumulation of small phenotypically mature malignant B 51 
lymphocytes in the blood, bone marrow and lymph nodes 1. CLL may be preceded by monoclonal 52 
B-cell lymphocytosis, which evolves to CLL through genetic changes including somatic mutations 53 
and chromosomal aberrations 1. Many patients are diagnosed at an asymptomatic stage and may 54 
not initially require treatment. Management of symptomatic patients includes chemotherapy with 55 
alkylating agents and purine analogues, combination of chemotherapy and immunotherapy, and 56 
drugs that target key signaling pathways 1, 2. Survival rates for patients with CLL have 57 
continuously improved mainly due to more efficient treatment 2, 3. Increased survival rates increase 58 
the likelihood of second primary cancers (SPCs), which may potentially interfere with survival. 59 
Elevated risks for SPC have been reported in patients with CLL, including non-melanoma skin 60 
cancer, melanoma, sarcoma, and lung, renal and prostate cancers 4, 5. It was reported that CLL 61 
patients with second malignancies have a worse relative survival than non-CLL patients with the 62 
same second malignancies 6, 7. 63 
 64 
HCL is a B-cell disease with common somatic BRAF mutations. Many patients have an indolent 65 
course and no therapies are required 8. Therapies were developed in 1990 based on purine 66 
analogues, which achieved good response rates, and more recently targeted treatments have 67 
become available including inhibition of the mutated BRAF kinase 8. Since 1990, relative survival 68 
 3
has been close to the background population among patients diagnosed before the age of 60 years 69 
and has now improved to approximately 90% even among elderly people 8. Increased risks of 70 
SPCs in HCL patients have been reported for Hodgkin and non-Hodgkin lymphoma (NHL) and for 71 
thyroid cancer 9, 10.    72 
 73 
We used data from the Swedish Cancer Registry to assess survival in CLL and HCL with and 74 
without SPCs. In addition, we grouped SPCs into three ‘prognostic groups’ based on 5-year 75 
relative survival of these cancers as first primary cancer 11, 12: ‘good survival’ (relative survival 76 
>60%) included cancers in the lip, larynx, anus, breast, cervix, endometrium, prostate, testis, male 77 
genitals, kidney, bladder, melanoma, skin (squamous cell, SCC), eye, thyroid gland and endocrine 78 
and Hodgkin lymphoma; ‘moderate survival’ (40-60%) included cancers in the remaining upper 79 
aerodigestive tract, salivary glands, small intestine, colorectum, female genitals, bone and 80 
connective tissue and non-Hodgkin lymphoma; ‘poor survival’ (<40%) included cancers in the 81 
stomach, esophagus, liver, pancreas, lung, ovary and nervous system and myeloma. Relative 82 
survival was calculated by using the observed survival in the patient cohort divided by the 83 
expected survival obtained from the general cancer-free population (which can be identified using 84 
the data from the nation-wide cancer registry), matched on age, sex, calendar period, county and 85 
socioeconomic status. The expected survival was calculated with the Ederer II method 13. The 86 
standard error of the observed survival was estimated by Greenwood’s formula 14. Patients 87 
diagnosed between 1991 and 2015 were included in the study. Relative survival in adult patients (> 88 
20 years), with and without SPC, was measured from the time of diagnosis until death, 89 
immigration or 2015, whichever came first. Multivariable Cox proportional hazard regression 90 
model adjusting sex, age and calendar year of first cancer diagnosis and socioeconomic status was 91 
applied to assess hazard ratios (HRs) and linear trends of HRs among patients with SPC in 92 
different prognostic groups compared to patients without SPC. In this model, the diagnosis of SPC 93 
was treated as a time-dependent variable in order to avoid the immortal time bias 15. Trend test was 94 
performed by considering patients without any SPC, with SPC of good, moderate and poor 95 
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prognosis as continuous variable. All statistical analyses were performed in SAS (version 9.4) and 96 
R software. The study was approved by the ethical committee of the University of Lund. 97 
 98 
Among 9 338 CLL patients, a total of 1571 were diagnosed with SPC (16.8%) after a median 99 
(interquartile, 1-7) follow-up time of four years; 5 639 deaths were recorded and of these 1122 100 
(19.9%) were in patients diagnosed with a SPC. Among 718 HCL patients, a total of 119 were 101 
diagnosed with SPC (16.6%) after a median (interquartile, 2-11) follow-up time of seven years; of 102 
234 HCL deaths, 57 (24.4%) were recorded in patients with SPC. For CLL patients with second 103 
cancer of poor prognosis, the main two SPCs were lung and brain cancers, for those with moderate 104 
prognosis, they were non-Hodgkin lymphoma and colorectal cancer, and for those with good 105 
prognosis, they were skin (squamous cell) and prostate cancers. In HCL patients with second 106 
cancer, the main two SPCs were the same as with CLL in three groups of different prognosis. 107 
Corresponding case numbers, relative survival and 95% confidence intervals (CIs) for CLL are 108 
detailed in Supplementary Table 1.  109 
 110 
Fig. 1 shows relative survival for CLL and HCL, with and without SPC, and in patients with SPC 111 
in the three prognostic groups. For CLL, survival was significantly better (non-overlapping 112 
95%CIs) for patients with SPC compared to those without SPC in the first year and years 2 to 5 113 
after diagnosis (Fig. 1a, and Supplementary Table 1). The survival rate was reversed in subsequent 114 
years but was not significant. For HCL, the data between patients with and without SPC were 115 
essentially similar: in year 1, patients with SPC had significantly better survival than those without 116 
SPC but survival was reversed at subsequent periods, yet the differences were not significant (Fig. 117 
1b, Supplementary Table 1). CLL patients in the good prognostic group showed excellent survival 118 
during the first years but with time the rate equalized with that of moderate prognosis (Fig. 1c). In 119 
the poor prognostic group, survival was lower at all follow-up times and the rates differed 120 
significantly from patients without SPC in follow-up times after year 1. For HCL the survival of 121 
good and moderate prognosis patients did not differ but those for poor prognosis were modestly 122 
suppressed (significant for years 7 to 16 years compared to patients without SPC).   123 
 5
 124 
Patients had to survive some time to be diagnosed with SPC, which is a condition for immortality 125 
bias. To better understand the effect of different prognostic groups on the survival in SPC, a time 126 
dependent analysis was necessary to avoid the bias. Multivariable Cox proportional hazard 127 
regression was performed by treating SPC diagnosis as time-dependent variable stratified in 128 
prognostic groups (Table 1). CLL patients with diagnosis of SPC of good prognosis experienced 129 
worse survival compared to those without any SPC diagnosis (HR=1.76, 95%CI: 1.61-1.92). 130 
Patients with SPC of moderate (HR=2.18, 1.76-2.70) and poor prognosis (HR=5.83, 4.83-7.03) 131 
survived even worse. The trend test for HRs was highly significant (P-trend=2×10-16). For HCL, 132 
the HRs for patients with SPCs of good, moderate and poor prognosis were respectively 1.69 133 
(1.11-2.57), 2.15 (0.92, 5.02) and 13.34 (4.92-36.33) and the trends were also significant (P-134 
trend=5×10-6).      135 
 136 
The data shows that even for cancers with relatively good overall survival, those with SPC are a 137 
subgroup for whom survival may essentially deviate from patients without SPC and who may often 138 
be forgotten in prognostic evaluations. SPCs are a challenging issue concerning cancer survival 139 
and attempts to increase patient outcome cannot disregard the effect of SPCs. We tested, for the 140 
first time, the hypothesis that survival in SPCs would follow the survival experience known for 141 
first primary cancers. The hypothesis appeared to be correct and the trend tests between prognostic 142 
groups were highly significant, especially for CLL with large case numbers. Patients with SPC 143 
presented good survival in the early stage of follow-up time which is known as immortal time but 144 
experienced poor survival after diagnosis of SPC. This pattern of survival may indicate that some 145 
active drugs have led to better outcomes early but also caused mutations that subsequently lead to 146 
second malignancies. 147 
 148 
Early mortality in CLL and HCL may be caused by severe infections. If the patient dies, SPCs may 149 
remain underreported. Another reason for underreporting of SPCs could be less vigilant diagnostic 150 
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procedures in ill or frail patients 16. Such underreporting may be a complication in survival studies 151 
thus masking the influence of SPCs but can be detected in the analysis of follow-up trends.  152 
 153 
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FIGURE LEGEND  249 
 250 
Fig. 1 Relative survival for CLL and HCL patients with and without SPC (a and b) and in patients 251 
with SPC in the three prognostic groups (c and d). SPC, second primary cancer, CLL, chronic 252 
lymphocytic leukemia, HCL, hairy cell leukemia 253 

  
Table 1. Hazard ratio in patients diagnosed with SPC of different prognostic classes compared to 
those without SPC  
 
Years since 
diagnosis 
SPC of good prognosis SPC of moderate 
prognosis 
SPC of poor prognosis P trend 
N HR (95% CI) N HR (95% CI) N HR (95% CI) 
CLL 681 1.76 (1.61-1.92) 177 2.18 (1.76-2.70) 220 5.83 (4.83-7.03) 2×10-16 
HCL 31 1.69 (1.11-2.57) 11 2.15 (0.92-5.02) 9 13.34 (4.92-36.33) 5×10-6 
Diagnosis of second cancer of unknown primary was not considered in any prognostic groups. 
